Faes Farma Future Growth
Future criteria checks 0/6
Faes Farma's earnings are forecast to decline at 1.1% per annum while its annual revenue is expected to grow at 1.9% per year. EPS is expected to decline by 1.3% per annum. Return on equity is forecast to be 11.4% in 3 years.
Key information
-1.1%
Earnings growth rate
-1.3%
EPS growth rate
Pharmaceuticals earnings growth | 14.8% |
Revenue growth rate | 1.9% |
Future return on equity | 11.4% |
Analyst coverage | Low |
Last updated | 26 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 499 | 89 | 94 | 107 | 3 |
12/31/2025 | 497 | 92 | 79 | 110 | 4 |
12/31/2024 | 476 | 90 | 55 | 104 | 3 |
12/31/2023 | 473 | 92 | -1 | 101 | N/A |
9/30/2023 | 472 | 90 | N/A | N/A | N/A |
6/30/2023 | 469 | 90 | -9 | 97 | N/A |
3/31/2023 | 467 | 91 | N/A | N/A | N/A |
12/31/2022 | 462 | 89 | 26 | 107 | N/A |
9/30/2022 | 460 | 86 | N/A | N/A | N/A |
6/30/2022 | 466 | 88 | 50 | 113 | N/A |
3/31/2022 | 449 | 88 | N/A | N/A | N/A |
12/31/2021 | 429 | 82 | 20 | 80 | N/A |
9/30/2021 | 416 | 81 | N/A | N/A | N/A |
6/30/2021 | 398 | 74 | 8 | 56 | N/A |
3/31/2021 | 394 | 73 | N/A | N/A | N/A |
12/31/2020 | 411 | 73 | 53 | 78 | N/A |
9/30/2020 | 408 | 77 | N/A | N/A | N/A |
6/30/2020 | 407 | 73 | 57 | 78 | N/A |
3/31/2020 | 409 | 68 | N/A | N/A | N/A |
12/31/2019 | 383 | 64 | 46 | 68 | N/A |
9/30/2019 | 379 | 60 | N/A | N/A | N/A |
6/30/2019 | 363 | 59 | 51 | 74 | N/A |
3/31/2019 | 351 | 54 | N/A | N/A | N/A |
12/31/2018 | 340 | 52 | 40 | 59 | N/A |
9/30/2018 | 334 | 51 | N/A | N/A | N/A |
6/30/2018 | 330 | 49 | 40 | 58 | N/A |
3/31/2018 | 308 | 47 | N/A | N/A | N/A |
12/31/2017 | 282 | 41 | 25 | 42 | N/A |
9/30/2017 | 266 | 39 | N/A | N/A | N/A |
6/30/2017 | 250 | 39 | N/A | 43 | N/A |
3/31/2017 | 241 | 38 | N/A | N/A | N/A |
12/31/2016 | 237 | 37 | N/A | 50 | N/A |
9/30/2016 | 226 | 35 | N/A | N/A | N/A |
6/30/2016 | 222 | 34 | N/A | 40 | N/A |
3/31/2016 | 220 | 32 | N/A | N/A | N/A |
12/31/2015 | 214 | 30 | N/A | 41 | N/A |
9/30/2015 | 207 | 28 | N/A | N/A | N/A |
6/30/2015 | 203 | 27 | N/A | 42 | N/A |
3/31/2015 | 196 | 26 | N/A | N/A | N/A |
12/31/2014 | 198 | 25 | N/A | 32 | N/A |
9/30/2014 | 195 | 23 | N/A | N/A | N/A |
6/30/2014 | 194 | 24 | N/A | 20 | N/A |
3/31/2014 | 192 | 20 | N/A | N/A | N/A |
12/31/2013 | 193 | 23 | N/A | 32 | N/A |
9/30/2013 | 196 | 21 | N/A | N/A | N/A |
6/30/2013 | 197 | 23 | N/A | 31 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0K9H's earnings are forecast to decline over the next 3 years (-1.1% per year).
Earnings vs Market: 0K9H's earnings are forecast to decline over the next 3 years (-1.1% per year).
High Growth Earnings: 0K9H's earnings are forecast to decline over the next 3 years.
Revenue vs Market: 0K9H's revenue (1.9% per year) is forecast to grow slower than the UK market (3.4% per year).
High Growth Revenue: 0K9H's revenue (1.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0K9H's Return on Equity is forecast to be low in 3 years time (11.4%).